Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Video

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.

Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

Russ Conroy
May 24th 2025
Article

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Investigators plan to share detailed results from the RC48-C016 trial at future international academic conferences in 2025.

Disitamab Vedotin Combo Extends PFS/OS in HER2+ Urothelial Carcinoma

Russ Conroy
May 17th 2025
Article

Treatment with disitamab vedotin and toripalimab improves survival regardless of cisplatin eligibility or HER2 expression level in the phase 3 RC48-C016 trial.

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.